Status:
COMPLETED
A Safety PK/PD Study of SLV337 in Patients With Type 2 Diabetes
Lead Sponsor:
Abbott Products
Collaborating Sponsors:
Quintiles, Inc.
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SLV337 in patients with type 2 diabetes
Eligibility Criteria
Inclusion
- Inclusion Criteria Type 2 diabetes ,stable dose of Metformin,HbA1c \>= 7%, but \< 9% Exclusion Criteria Type 1 diabetes mellitus, Body Mass Index (BMI) \>40.0 kg/m2, evidence of unstable cardiovascular diseases, NYHA class I to IV, ALT \> 1.5 times UNL, creatinine clearance \<60 mL/min
Exclusion
Key Trial Info
Start Date :
December 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00924534
Start Date
December 1 2009
End Date
December 1 2010
Last Update
January 4 2012
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 54183
Dimitrovgrad, Bulgaria, 6400
2
Site Reference ID/Investigator# 54182
Pleven, Bulgaria, 5800
3
Site Reference ID/Investigator# 44722
Plovdiv, Bulgaria, 4000
4
Site Reference ID/Investigator# 44723
Sofia, Bulgaria, 1407